Key stats
About iShares Biotechnology ETF
Home page
Inception date
Feb 5, 2001
Structure
Open-Ended Fund
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
BlackRock Fund Advisors
Distributor
BlackRock Investments LLC
IBB tracks an index of US biotechnology companies listed on the major US exchanges. This includes companies engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. This also includes companies that are engaged in the production of tools or systems that enable biotechnology processes. IBB includes companies of all capitalizations, and weights using a modified market-cap methodology. Individual holdings are subject to capping requirements, 8% on the five largest constituents and 4% for the remaining. The index is rebalanced quarterly and fully reconstituted annually in December. Prior to June 21, 2021, the fund was named iShares Nasdaq Biotechnology ETF and tracked the NASDAQ Biotechnology Index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.82%
Health Technology97.29%
Commercial Services1.81%
Technology Services0.55%
Health Services0.15%
Process Industries0.02%
Bonds, Cash & Other0.18%
Cash0.18%
Miscellaneous0.00%
Stock breakdown by region
North America88.92%
Europe10.56%
Asia0.38%
Oceania0.14%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
IBB invests in stocks. The fund's major sectors are Health Technology, with 97.29% stocks, and Commercial Services, with 1.81% of the basket. The assets are mostly located in the North America region.
IBB top holdings are Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated, occupying 8.53% and 8.26% of the portfolio correspondingly.
IBB last dividends amounted to 0.12 USD. The quarter before, the issuer paid 0.06 USD in dividends, which shows a 48.53% increase.
IBB assets under management is 5.27 B USD. It's fallen 0.91% over the last month.
IBB fund flows account for −1.28 B USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, IBB pays dividends to its holders with the dividend yield of 0.32%. The last dividend (Mar 21, 2025) amounted to 0.12 USD. The dividends are paid quarterly.
IBB shares are issued by BlackRock, Inc. under the brand iShares. The ETF was launched on Feb 5, 2001, and its management style is Passive.
IBB expense ratio is 0.45% meaning you'd have to pay 0.45% of your investment to help manage the fund.
IBB follows the NYSE Biotechnology (TR). ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
IBB invests in stocks.
IBB price has risen by 1.64% over the last month, and its yearly performance shows a −11.93% decrease. See more dynamics on IBB price chart.
NAV returns, another gauge of an ETF dynamics, showed a −12.57% decrease in three-month performance and has decreased by −11.01% in a year.
NAV returns, another gauge of an ETF dynamics, showed a −12.57% decrease in three-month performance and has decreased by −11.01% in a year.
IBB trades at a premium (0.03%) meaning the ETF is trading at a higher price than the calculated NAV.